Sugi Predict

Sugi Predict / Compounds / SCHEMBL194251

SCHEMBL194251

SCHEMBL194251

NOc1ccccc1C(=O)Oc1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 0.59
▸ HSD17B10 Q99714 4/20 0.59
▸ HPGD P15428 3/20 0.59
▸ ALOX15 P16050 1/20 0.59
▸ ALDH1A1 P00352 4/20 0.58
▸ TSHR P16473 1/20 0.58
▸ KMT2A Q03164 1/20 0.58
▸ KDM4E B2RXH2 3/20 0.56
▸ TDP1 Q9NUW8 1/20 0.56
▸ LMNA P02545 3/20 0.54
▸ CYP1A2 P05177 2/20 0.52
▸ CYP2C9 P11712 2/20 0.52
▸ CYP2C19 P33261 1/20 0.52
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ SLC6A3 Q01959 2/20 0.50
▸ TP53 P04637 1/20 0.50
▸ CYP3A4 P08684 1/20 0.50
▸ ADORA3 P0DMS8 1/20 0.50
▸ CHRM1 P11229 1/20 0.50
▸ TBXA2R P21731 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10781495 0.84 HSD17B10 (0.60) MAPTHSD17B10HPGDALOX15ALDH1A1
SCHEMBL1282647 0.83 HSD17B10 (0.64) MAPTHSD17B10HPGDALOX15ALDH1A1
SCHEMBL8072099 0.83 HSD17B10 (0.61) MAPTHSD17B10HPGDALOX15ALDH1A1
SCHEMBL767125 0.83 CTNNB1 (0.65) MAPTHSD17B10HPGDALOX15ALDH1A1
SCHEMBL5710896 0.83 HSD17B10 (0.64) MAPTHSD17B10HPGDALOX15ALDH1A1
SCHEMBL29437924 0.82 HSD17B10 (0.76) MAPTHSD17B10HPGDALOX15ALDH1A1
SCHEMBL69868 0.82 HSD17B10 (0.76) MAPTHSD17B10HPGDALOX15ALDH1A1
SCHEMBL14152348 0.81 HSD17B10 (0.62) MAPTHSD17B10HPGDALOX15ALDH1A1
SCHEMBL4392121 0.81 HSD17B10 (0.62) MAPTHSD17B10HPGDALOX15ALDH1A1
SCHEMBL2149614 0.81 MAPT (0.71) MAPTHSD17B10HPGDALOX15ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1414 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025111482-A1 COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS BEXSON BIOMEDICAL, INC. (US) 2025-05-30 — — WO claimed
US-20230003721-A1 MITOTHERAPEUTICS FOR THE TREATMENT OF BRAIN DISORDERS THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. 2023-01-05 — — US claimed
CN-114829556-A Polymeric surfactant compounds 路博润公司 2022-07-29 — — CN claimed
US-20220169680-A1 CELL-PENETRATING PEPTIDE BASED ON INFLUENZA VIRUS M2 PROTEIN INSTITUTE OF BASIC MEDICAL SCIENCES CHINESE ACADEMY OF MEDICAL SCIENCES (CN) 2022-06-02 — — US claimed
EP-3912989-A1 CELL-PENETRATING PEPTIDE BASED ON INFLUENZA VIRUS M2 PROTEIN Institute of Basic Medical Sciences Chinese Academy of Medical Sciences (CN) 2021-11-24 — — EP claimed
WO-2021127183-A1 POLYMERIC SURFACTANT COMPOUND THE LUBRIZOL CORPORATION (US) 2021-06-24 — — WO claimed
US-10377779-B2 Carbonate prodrugs and methods of using the same ACORDA THERAPEUTICS, INC. (US) 2019-08-13 — — US claimed
US-20180086778-A1 CARBONATE PRODRUGS AND METHODS OF USING THE SAME NEUROGESX, INC. 2018-03-29 — — US claimed
US-20130252945-A1 AMORPHOUS BIOINORGANIC IONIC LIQUID COMPOSITIONS COMPRISING PHARMACEUTICALS LOS ALAMOS NAT SECURITY LLC (US) 2013-09-26 — — US claimed
EP-2560634-A1 NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS Piramal Enterprises Limited (IN) 2013-02-27 — — EP claimed
EP-1252133-A2 PHARMACEUTICAL COMPOUNDS NICOX S.A. (FR) 2002-10-30 — — EP claimed
CN-1358178-A Pharmaceutical compounds NICOX SA (FR) 2002-07-10 — — CN claimed
CN-1354740-A Pharmaceutical compounds NICOX SA (FR) 2002-06-19 — — CN claimed
EP-1169294-A2 PHARMACEUTICAL COMPOUNDS NICOX S.A. (FR) 2002-01-09 — — EP claimed
EP-1169298-A2 PHARMACEUTICAL COMPOUNDS NICOX S.A. (FR) 2002-01-09 — — EP claimed
WO-2001012584-A2 PHARMACEUTICAL COMPOUNDS NICOX S.A. (FR) 2001-02-22 — — WO claimed
WO-2000061541-A2 PHARMACEUTICAL COMPOUNDS NICOX S.A. (FR) 2000-10-19 — — WO claimed
WO-2000061537-A2 PHARMACEUTICAL COMPOUNDS NICOX S.A. (FR) 2000-10-19 — — WO claimed
EP-0046270-B1 NOVEL DERIVATIVES OF BIO-AFFECTING PHENOLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITION CONTAINING THEM INTERx RESEARCH CORPORATION (US) 1986-05-21 — — EP claimed
EP-0046270-A1 Novel derivatives of bio-affecting phenolic compounds and pharmaceutical composition containing them INTERx RESEARCH CORPORATION (US) 1982-02-24 — — EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10377779-B2 Carbonate prodrugs and methods of using the same CA6, CA7, CA4 MAPT 3060/4885HSD17B10 702/4885HPGD 238/4885
US-20130252945-A1 AMORPHOUS BIOINORGANIC IONIC LIQUID COMPOSITIONS COMPRISING PHARMACEUTICALS MCOLN1, PYM1, MCOLN2 MAPT 306/4885HSD17B10 4621/4885HPGD 3568/4885
US-20180086778-A1 CARBONATE PRODRUGS AND METHODS OF USING THE SAME CA6, CA7, CA4 MAPT 3060/4885HSD17B10 702/4885HPGD 238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.